Aerie Pharmaceuticals, Inc.announced that it has initiated the dosing in a phase II study on netarsudil ophthalmic solution in Japan for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
a manufacturer of pharmaceutical products
Industry PharmaceuticalsOther